NIH grants over $500 million to develop antiviral drugs for potential future pandemics
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
NIH grants over $500 million to develop antiviral drugs for potential future pandemics
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
NIH grants over $500 million to develop antiviral drugs for potential future pandemics
The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), has awarded approximately $577 million to establish nine Pandemic Pathogen Antiviral Drug Discovery (AViDD) centers.
The AViDD Center will conduct innovative multidisciplinary research to develop candidate COVID-19 antivirals, as well as antivirals targeting specific virus families that may cause future pandemics, including paramyxoviruses, bunyaviruses, togaviruses , filoviruses (including Ebola virus and Marburg virus), picornaviruses (including enteroviruses and other viruses that cause colds), flaviviruses (including those that cause yellow fever, dengue fever, and Zika), etc. .
The grant is part of the Pandemic Antiviral Initiative, an intensive research program aimed at accelerating the development of treatments for COVID-19.
The AViDD Center will conduct early identification and validation studies of novel viral targets, with a focus on identifying small molecules and biotherapeutics that directly block viral targets.
After drug candidates are identified and properties such as potency and breadth are evaluated, the most promising drugs move into late-stage preclinical development.
“Our hope is that research on antiviral drugs will better prepare us for the next pandemic,” said NIAID Director Dr. Anthony S. Fauci.
References:
[1] NIH announces antiviral drug development awards. Retrieved May 18, 2022, from https://www.nih.gov/news-events/news-releases/nih-announces-antiviral-drug-development-awards
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.